A Challenging Cutaneous Lesion in a Patient With Chronic Idiopathic Neutropenia

Aikaterini Gkoufa, Pagona Sklapani, Nikolaos Trakas, Vasiliki E. Georgakopoulou

Abstract

Ecthyma gangrenosum (EG) is an uncommon necrotizing vasculitis that affects mainly immunocompromised and burn patients, and it is frequently associated with *Pseudomonas aeruginosa* bacteremia. However, cases of EG with other related pathogens and cases of EG affecting immunocompetent hosts have also been described in the literature. Besides, less common cases of EG without bacteremia have been reported. Herein, we describe a rare case of EG due to *Pseudomonas aeruginosa* without bacteremia in a patient with chronic idiopathic neutropenia (CIN). Considering the high mortality rate associated with EG, early diagnosis and appropriate effective treatment are crucial.

Categories: Dermatology, Internal Medicine, Infectious Disease
Keywords: pseudomonas aeruginosa, cutaneous lesion, immunosuppression, neutropenia, ecthyma gangrenosum

Introduction

Ecthyma gangrenosum (EG) is a rare skin lesion first reported by Barker in 1897 [1]. It is often defined as a cutaneous manifestation of *Pseudomonas aeruginosa* septicemia; however, cases of EG that occurred without bacteremia have also been described [2]. Furthermore, *Pseudomonas aeruginosa* is not the only causative pathogen for these necrotic lesions, and various organisms may be identified [2].

The bacteremic type of EG is more common than the non-bacteremic one. In the bacteremic type, EG results from perivascular bacterial invasion of the media and adventitia of arteries and veins, with secondary ischemic necrosis of the surrounding skin. In the non-bacteremic type, the lesions are formed at the location of direct inoculation into the epidermis [2]. EG commonly begins as painless red macules that rapidly evolve into pustules and/or bullae. Ultimately, these become gangrenous ulcers [3].

The common risk factors for EG development include neutropenia, leukemia, diabetes mellitus, malnutrition, infancy, and old age, because of their underdeveloped or compromised immune system, recent viral illness, hypogammaglobulinemia, malignancies, and extensive burn wounds [4]. Ecthyma gangrenosum can occur in all age groups and genders, and although the majority of the cases are described in immunocompromised hosts, EG has also been described in immunocompetent individuals [5].

Chronic idiopathic neutropenia (CIN) in adults is an uncommon neutrophil disorder characterized by the continuous and unexplained decreased peripheral blood neutrophil count for a prolonged time period in the absence of evidence of any existing condition that might be associated with neutropenia and in the context of negative antineutrophil antibody testing and normal bone marrow (BM) morphology and karyotype, which exclude cases of myelodysplastic syndrome presenting as isolated neutropenia [6]. The pathophysiologic mechanism of CIN is related to an inflammatory BM microenvironment. This microenvironment consists of pro-inflammatory cytokines that induce myelosuppression, leading to the accelerated apoptosis of the granulocytic progenitor cells [7].

Herein, we report a rare case of EG without bacteremia in a patient with CIN.

Case Presentation

A 67-year-old male with a medical history of CIN and colonization of a multidrug-resistant *Pseudomonas* spp. was admitted to the emergency department because of a fever of up to 38.5°C of two days duration. On admission, the patient complained of a new-onset painful skin lesion of the abdominal wall with an erythematous halo surrounding a dark gray necrotic nodule (Figure 1A). He was hemodynamically stable and febrile.

The clinical examination revealed the already known splenomegaly. Laboratory analysis showed low white blood cell count, with low neutrophil count, and elevated levels of C-reactive protein (CRP). In addition,
blood cultures and cultures of the skin lesion were obtained.

An antimicrobial treatment with intravenous colistin at a loading dose of 9.000.000 IU followed 12 hours later by a dose of 4.500.000 IU every 12 hours combined with intravenous gentamycin 240 mg once daily and intravenous vancomycin 1 gr twice daily was administrated.

*Pseudomonas aeruginosa* was isolated from the ulcer’s culture; however, numerous blood cultures were sterile. Three days after the patient’s presentation, the susceptibility testing of *Pseudomonas aeruginosa* was available, so antimicrobial treatment was deescalated to intravenous piperacillin/tazobactam 4.0-5 g four times daily, and on the fourth day of intravenous antimicrobial treatment with piperacillin/tazobactam and clinical improvement, the patient was discharged and was advised to continue his treatment with oral ciprofloxacin for seven days until reevaluation. Figure 1B shows the improvement of the skin lesion after successful treatment.

**FIGURE 1:** Ecthyma gangrenosum in a patient with chronic idiopathic neutropenia.

A: Ecthyma gangrenosum at initial presentation; skin lesion of the abdominal wall with an erythematous halo surrounding a dark gray necrotic nodule (arrow). B: Ecthyma gangrenosum after successful treatment (arrow).

**Discussion**

Our case is rare for two reasons. Firstly, it describes a case of EG without bacteremia, which is the less common type of EG. Secondly, to the best of our knowledge, our case is the first to report the presence of EG due to *Pseudomonas aeruginosa* in a patient with CIN.

This skin lesion without bacteremia has been described in heart, kidney, and bone marrow transplant recipients [8-10]. It has also been described in neutropenic patients [11]. Furthermore, it has been reported in patients with various types of immunosuppression, such as human immune virus (HIV) infection and Good syndrome, a rare association of thymoma and immunodeficiency [12,13]. EG without bacteremia has been also mentioned in leukemic patients [14]. Besides, EG without bacteremia due to *Pseudomonas aeruginosa* has been described in previously healthy individuals [15,16]. Of interest, according to a case series by Huminer et al., the most important difference between patients with EG with bacteremia and patients with EG without bacteremia was a significantly lower mortality rate in non-bacteremic patients [11].

CIN is a relatively rare disorder. In a study by Andersen et al., among a Danish health service database of 570,000 individuals, the prevalence of CIN was 0.12% [17]. In another study from the island of Crete, in our country, the prevalence of CIN in adults was 1.4%, with no cases of severe neutropenia among 778 adults [18]. In Washington, USA, the estimated prevalence of severe CIN is approximately five cases per million [6]. For several years, there was no effective treatment for CIN. Numerous studies have now confirmed the effectiveness of granulocyte colony-stimulating factor (G-CSF) for the treatment of severe CIN and for the reduction of infection-related events and antibiotic use [19].

However, it has been reported that these patients are mainly vulnerable to respiratory, periodontal, and skin infections and oral ulcers, despite receiving G-CSF [6]. Thus, the role of early clinical suspicion of the diagnosis of EG may be crucial due to its rarity and taking into account that the mortality rate of EG ranges from 38% to 96% in cases with bacteremia and from 7% to 15% in non-bacteremic patients [20].
Conclusions
This is a rare case of EG without bacteremia in a patient with CIN. The case indicates that EG may develop even in the absence of bacteremia in this patients’ group, and it should be suspected as a possible diagnosis even in the absence of positive blood cultures. Considering the high mortality rate, early recognition and appropriate effective treatment are mandatory.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Funk E, Ivan D, Gillenwater AM: Ecthyma gangrenosum: an unusual cutaneous manifestation of the head and neck. Arch Otolaryngol Head Neck Surg. 2009, 135:818-20. 10.1001/archoto.2009.95
2. Vaiman M, Lazarovich T, Heller L, Lotan G: Ecthyma gangrenosum and ecthyma-like lesions: review article. Eur J Clin Microbiol Infect Dis. 2015, 34:633-9. 10.1007/s10096-014-2277-4
3. Korte AK, Vos JM: Ecthyma gangrenosum. N Engl J Med. 2017, 377:e52. 10.1056/NEJMcm1702302
4. Martínez-Longoria CA, Rosales-Solis GM, Ocampo-Garza J, Guerrero-Gonzalez GA, Ocampo-Candiani J: Ecthyma gangrenosum: a report of eight cases. An Bras Dermatol. 2017, 92:698-700. 10.1590/abd1806-4841.20175580
5. Biscaye S, Demonchy D, Afnanetti M, Dupont A, Haas H, Tran A: Ecthyma gangrenosum, a skin manifestation of Pseudomonas aeruginosa sepsis in a previously healthy child: a case report. Medicine (Baltimore). 2017, 96:e5507. 10.1097/MD.0000000000005507
6. Dale DC, Bolyard AA: An update on the diagnosis and treatment of chronic idiopathic neutropenia. Curr Opin Hematol. 2017, 24:46-53. 10.1097/MOH.0000000000000505
7. Newburger PE, Dale DC: Evaluation and management of patients with isolated neutropenia. Semin Hematol. 2015, 50:198-206. 10.1053/j.seminhematol.2015.06.010
8. Hamed A, Niehaus AG, Bushardt Hughes O, Jalkharia N: Ecthyma gangrenosum without bacteremia in a 54-year-old woman with heart transplant. Transpl Infect Dis. 2020, 22:e13519. 10.1111/tid.13519
9. Santos B, Sanz M, Nuñez A, Mayor LQ, Quiroga R: Ecthyma gangrenosum in a renal transplant recipient. Nefrologia. 2016, 36:573-4. 10.1016/j.nefro.2016.06.005
10. Krishna K: Ecthyma gangrenosum without bacteremia. Indian J Dermatol Venereol Leprol. 1996, 62:202-5.
11. Humerin D, Siegman-Igra Y, Morduchowicz G, Pitlik SD: Ecthyma gangrenosum without bacteremia. Report of six cases and review of the literature. Arch Intern Med. 1987, 147:299-301. 10.1001/archinte.147.2.299
12. Nelson MR, Barton SE, Langtrey JA, Gazzard BG: Ecthyma gangrenosum without bacteremia in an HIV seropositive male. Int J STD AIDS. 1991, 2:295-6. 10.1177/095646249100200417
13. Ferguson L, Chong H, Singh M: Ecthyma gangrenosum without bacteremia: evidence in favour of a broader definition. Clin Exp Dermatol. 2017, 42:524-7. 10.1111/ced.13064
14. Singh TN, Devi KM, Devi KS: Ecthyma gangrenosum: a rare cutaneous manifestation caused by Pseudomonas aeruginosa without bacteremia in a leukaemic patient—a case report. Indian J Med Microbiol. 2005, 23:262-5.
15. Bozkurt I, Yüksel EP, Sunbul M: Ecthyma gangrenosum in a previously healthy patient. Indian Dermatol Online J. 2015, 6:536-8. 10.4103/2229-5178.164479
16. Sarkar S, Patra AK, Mondal M: Ecthyma gangrenosum in the periorbital region in a previously healthy immunocompetent woman without bacteremia. Indian Dermatol Online J. 2016, 7:536-9. 10.4103/2229-5178.174326
17. Andersen CL, Tesfa D, Siersma VD, et al.: Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study. J Intern Med. 2016, 279:566-75. 10.1111/joim.12467
18. Papadaki HA, Xylouri I, Coulocheri S, Kalmaniti M, Kafatos A, Eliopoulos GD: Prevalence of chronic idiopathic neutropenia of adults among an apparently healthy population living on the island of Crete. Ann Hematol. 1999, 78:293-7. 10.1007/s002770050518
19. Dale DC, Bonilla MA, Davis MW, et al.: A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood. 1993, 81:2496-502.
20. Son YM, Na SY, Lee HY, Baek JO, Lee JR, Roh JY: Ecthyma gangrenosum: a rare cutaneous manifestation caused by Stenotrophomonas maltophilia in a leukemic patient. Ann Dermatol. 2009, 21:389-92. 10.5021/ad.2009.21.4.389